Alvin & Lois Lapidus Cancer Baltimore, MD - 21215

Alvin & Lois Lapidus Cancer is categorized under Hospitals in Baltimore, MD and active since 2000.

Alvin & Lois Lapidus Cancer was established in 2000, and today employs 1 to 4, earning $2.500.000 to $4.999.999 per year. This is a Hospitals business, which does work in the B2C market, and is classified as a Hospitals, under code number 6223100 by the NAICS.

If you are seeking more information, feel free to contact Alan Levine at the company’s single location by writing to 2401 West Belvedere Avenue, Baltimore, Maryland MD 21215 or by phoning (410) 601-4688. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Alvin & Lois Lapidus Cancer
Contact Person: Alan Levine
Address: 2401 West Belvedere Avenue, Baltimore, Maryland 21215
Phone Number: (410) 601-4688
Website Address: lifebridgehealth.org
Annual Revenue (USD): $2.500.000 to $4.999.999
Founded: 2000
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2C (Business to Consumer)
Business Category: Hospitals
SIC Code: 8062
NAICS Code: 6223100
Share This Business:

Alvin & Lois Lapidus Cancer was started in 2000 to provide professional Hospitals under the SIC code 8062 and NAICS code 6223100. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $2.500.000 to $4.999.999 per annum.

Feel free to contact Alan Levine for inquiries that concern Alvin & Lois Lapidus Cancer by calling the company number (410) 601-4688, as your correspondence is most welcome. Additionally, the physical location of the single location of Alvin & Lois Lapidus Cancer can be found at the coordinates 39.35391,-76.66318 as well as the street address 2401 West Belvedere Avenue in Baltimore, Maryland 21215.

For its online presence, you may visit Alvin & Lois Lapidus Cancer’s website at lifebridgehealth.org and engage with its social media outlets through on Twitter and on Facebook.